TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Problems

Premature ovarian insufficiency

Key Statistics

  • <40 yrs — Age cut-off (2 SD below 50±4)
  • 1% — Prevalence in women <40
  • >25 IU/l — ESHRE FSH threshold ×2, >4 WKS apart

Don't-miss facts

  1. POI = oligo-/amenorrhoea ≥4 months + FSH >25 IU/l on 2 occasions ≥4 weeks apart, aged <40 (ESHRE)

  2. Karyotype in every non-iatrogenic case regardless of age; FMR1 premutation testing only after counselling (family implications; male carriers → FXTAS)

  3. Autoimmune screen: ACA + 21OH-Ab + TPO-Ab; TPO-Ab positive → annual TSH. DEXA at diagnosis

  4. Continue HRT to age 50–51; target estradiol 180–370 pmol/l = 50–100 mcg patch or 2–4 mg oral daily

  5. Uterus present → add progestogen (continuous 100 mg micronised / MPA 2.5–5 mg / NET 1 mg; sequential 200 mg or MPA 10 mg ≥12 days/month). No uterus → estrogen only

  6. HRT is not contraception — spontaneous pregnancy in 5–10%; exclude pregnancy before/during workup

  7. Transdermal preferred in smokers, migraine, hypertension, VTE risk. COCP not recommended in migraine with aura; HRT not recommended after breast cancer (use gabapentin/venlafaxine/fluoxetine)

  8. Fertility = donor-oocyte IVF (high-risk pregnancy, hospital antenatal care). Cryopreservation has no role in established POI. GnRH agonist during chemotherapy reduces POI incidence

Red flags & must-not-miss

XY gonadal dysgenesis → 45% gonadal neoplasia risk — consider gonadectomy 21OH-Ab positive → latent Addison’s disease

Puberty induction: estrogen from age ≥12, progestogen delayed ≥2 years

Support: The Daisy Network · Turner Syndrome Support Society

Abbreviation Key

  • POI — premature ovarian insufficiency
  • BMD / DEXA — bone mineral density / dual-energy x-ray absorptiometry
  • ESHRE — European Society of Human Reproduction and
  • Embryology SCA / ACA — steroid cell / adrenocortical antibodies
  • BMS / NICE — British Menopause Society / National Institute for
  • 21OH-Ab / TPO-Ab — 21-hydroxylase / thyroid peroxidase Health and Care Excellence autoantibodies
  • FSH / LH / AMH — follicle-stimulating / luteinising hormone; anti- FMR1 /
  • FXPOI / FXTAS — Fragile-X mental retardation 1 gene / Müllerian hormone Fragile-X-associated POI / Fragile-X-associated tremor-ataxia syndrome
  • HRT / COCP — hormone replacement therapy / combined oral
  • contraceptive pill VTE / GnRH — venous thromboembolism / gonadotrophin-releasing hormone
  • CEE / MPA — conjugated equine estrogen / medroxyprogesterone acetate

Source: Sayed H, Jayaprakasan K. Premature ovarian insufficiency. The Obstetrician & Gynaecologist 2024;26:152–162. doi:10.1111/tog.12943

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free